Waveform

Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance

Retrieved on: 
木曜日, 5月 23, 2024
VTM, Infection, COVID-19, Automation, HIV, Waveform, Glycated hemoglobin, FX, Autoimmunity, POC, Movement, Acquisition, Operating cost, Research, Pharmaceutical industry

DUBLIN, Ireland, May 23, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the Company’s results for the quarter ended March 31, 2024.

Key Points: 
  • Our clinical laboratory revenues were $11.7m in Q1, 2024, a decrease of $1.0m or 7.6% compared to $12.7m in Q1, 2023.
  • Gross margin for Q1, 2024 was 37.6%, which was the same as the gross margin in Q1, 2023.
  • Net financial expenses in Q1, 2024 were $0.2m compared to $2.4m in Q1, 2023, a decrease of $2.2m.
  • The movement in the derivative financial asset led to financial income of $0.1m in Q1, 2024.

Gray Renews InvestigateTV+ For 2024-2025 Season

Retrieved on: 
木曜日, 4月 18, 2024
Investigation, News, Gray Television, Health, WAFB, WVUE, Journalism, Waveform, Growth

ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Gray Television, Inc. (“Gray” or the “Company”) (NYSE: GTN) announced today that its daily, 30-minute news magazine InvestigateTV+ is renewed for a second season in 2024-2025.

Key Points: 
  • ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Gray Television, Inc. (“Gray” or the “Company”) (NYSE: GTN) announced today that its daily, 30-minute news magazine InvestigateTV+ is renewed for a second season in 2024-2025.
  • The renewal is the direct result of impressive, double-digit ratings growth in the show’s debut season.
  • InvestigateTV+ built audience throughout its first season with an average of 25% growth with Adults 18+ across all Gray markets since its launch in September 2023 (Source: Nielsen).
  • “Our team is looking forward to another season providing our viewers with exclusive investigations, takeaways they can use in their daily lives, and inspiring stories about real people making a difference,” Powell said.

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates

Retrieved on: 
木曜日, 4月 4, 2024
CGM, Consultant, Negotiation, Conference, Growth, Data analysis, HIV, Himawari (satellites), Diabetes, World Health Organization, Acquisition, American depositary receipt, Diagnosis of HIV/AIDS, Units of paper quantity, Clinical trial, Injection, Balance sheet, Waveform, Pharmaceutical industry

DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.

Key Points: 
  • DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.
  • We expect to have fully executed this change by the end of 2024 and expect this will deliver significant annualised savings.
  • The assets and liabilities attributable to Fitzgerald Industries have been removed from our Consolidated Balance Sheet as of December 31, 2023.
  • Total revenues for Q4, 2023 were $13.4m which compares to $15.7m in Q4, 2022, a decrease of 14.6% and which were broken down as follows:

Trinity Biotech Announces Q3 2023 Financial Results & Business Update

Retrieved on: 
水曜日, 1月 31, 2024
USAID, Interim, Growth, ADS, CFO, Consultant, CGM, HIV, Diabetes, Intellectual property, Glucose meter, Interim management, American depositary receipt, Waveform, Service management, Des Fitzgerald, Acquisition, Units of paper quantity, Base rate, Q4, Pharmaceutical industry

DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023.

Key Points: 
  • DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023.
  • In our HIV business, shipments of Uni-Gold are expected to be lower than Q3, 2023 due to the typical irregular quarter on quarter ordering patterns in that business.
  • At June 30, 2023 and September 30, 2023, the assets and liabilities attributable to Fitzgerald Industries have been de-recognised from the Consolidated Balance Sheet.
  • Total revenues for Q3, 2023 were $14.7 million which compares to $15.7 million in Q3, 2022, a decrease of 6.5% and which were broken down as follows:

Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India

Retrieved on: 
水曜日, 1月 31, 2024
Partnership, Public, CGM, Diabetes, Patient, Glucose meter, Trinity, Physician, Bayer, Waveform, Acquisition, Letter, EST, Type 2 diabetes, Pharmaceutical industry

Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months.

Key Points: 
  • Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months.
  • In addition to the proposal to enter the Chinese market, the Letter of Intent includes a framework for the intention to launch a CGM device in India.
  • To date, CGM use in India is not widespread, but has been trending higher recently with increasing awareness about self-care.
  • Trinity Biotech will host a conference call on Wednesday, January 31 at 8:30 a.m. EST to discuss its recent Waveform acquisition.

Radome Market worth $5.8 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
水曜日, 12月 6, 2023
Longevity, Radames, Raytheon Technologies, Northrop Grumman, Commercial, Atmosphere of Earth, Investment, SATCOM, Frequency band, Weather, Wind, Mobile, Defense, Rain, Component, Communications satellite, Security, Communication, Growth, 3D, Frequency, Israel Aerospace Industries, SOTP, Radar, Economic development, Beauty salon, Instrumentation, Airline, Uncrewed vehicle, Application, Region, Waveform

Based on the offering, the solid laminate from radome body structure segment is estimated to lead the radome market from 2023 to 2028.

Key Points: 
  • Based on the offering, the solid laminate from radome body structure segment is estimated to lead the radome market from 2023 to 2028.
  • Based on the application, communication antenna segment is estimated to have the highest market share in 2023.
  • The communication antenna segment in radome market is projected to have the highest market share in 2023.
  • The Asia-Pacific region is expected to have the highest market share in the Radome Market in 2023.

Orthofix Announces Full Commercial Launch of the WaveForm L Interbody System for Lateral Lumbar Fusion Procedures

Retrieved on: 
月曜日, 11月 6, 2023
Medical Devices, Health, Hospitals, Surgery, Radiology, Biotechnology, 3D, Faculty, Spine, UCSD, Richard J. Wills Jr, Tissue engineering, MIS, Multimedia, Decompression, Wills, Growth, Surgeon, PEEK, ST, Waveform, Porosity, Patient, 3D printing, Gall

(NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the full U.S. commercial launch of the WaveForm® L Lateral Lumbar Interbody System.

Key Points: 
  • (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the full U.S. commercial launch of the WaveForm® L Lateral Lumbar Interbody System.
  • Designed for lateral lumbar interbody fusion (LLIF) procedures, the 3D-printed WaveForm L features a porous structure that prioritizes strength and stability to provide a robust fusion environment.
  • View the full release here: https://www.businesswire.com/news/home/20231106564293/en/
    The WaveForm® L Lateral Lumbar Interbody System is designed for lateral lumbar interbody fusion (LLIF) procedures.
  • The 3D-printed WaveForm L features a porous structure that prioritizes strength and stability to provide a robust fusion environment.

Perion Continues to Deliver Strong Results with 17% Year-Over-Year Increase in Revenue and 29% Growth in Adjusted EBITDA

Retrieved on: 
水曜日, 11月 1, 2023
Digital Marketing, Audio, Video, Finance, Artificial Intelligence, Advertising, Communications, Professional Services, Technology, QSR, WAVE, Waveform, Weather, Restaurant, Albertsons, CTV, Human, EBITDA, Digital, Perion Network, Learning, Retail media, Growth, Retail, Travel, TASE, AI, Display, Sales, Television, Video game

“Once again, our business results proved that our strategically diversified model gives us the agility to deliver continued growth,” stated Tal Jacobson, Perion’s CEO.

Key Points: 
  • “Once again, our business results proved that our strategically diversified model gives us the agility to deliver continued growth,” stated Tal Jacobson, Perion’s CEO.
  • “Despite macroeconomic headwinds, our third-quarter year-over-year revenue and adjusted EBITDA increased 17% and 29%, respectively.
  • These results were made possible by the ability to leverage our technological capabilities and focus resources on the strongest industry verticals to achieve top-line profitability and margin expansion.
  • Under our updated methodology, revenue generated from CTV in the third quarter of 2022 was $5.7 million vs. $7.4 million under the previous methodology.

Airborne Radars Market - Global Forecast to 2028: Demand for Phased Array Radars for Enhanced Operational Efficiency to Drive Market - ResearchAndMarkets.com

Retrieved on: 
火曜日, 10月 17, 2023
Air, Transport, Aerospace, Manufacturing, Investment, GPU, Region, Side looking airborne radar, Component, 3D, Security, Boeing Defense, Space & Security, USD, Northrop Grumman, Weather, Defense, KU, Digital, Hertz, Radar, Growth, Maintenance, Lockheed Martin, Saab AB, Israel Aerospace Industries, Leonardo S.p.A., Pulse, Raytheon Technologies, ASDE, Commercial, Research, FPGA, Thales Group, Uranium mining, Instrumentation, Communications satellite, Waveform

This report provides valuable insights for market leaders and newcomers alike in the airborne radars market.

Key Points: 
  • This report provides valuable insights for market leaders and newcomers alike in the airborne radars market.
  • North America is anticipated to hold the largest share in the airborne radars aircraft market in 2023, encompassing the US and Canada within this region.
  • The North American airborne radars market has seen significant growth recently, driven by a proactive approach to advancements and substantial investments in research and development within the airborne radars sector, poised to transform the radar market.
  • Several factors, including the growing demand for airborne weather monitoring and technological innovations in airborne radar systems, are expected to propel the airborne radars market.

Orthofix Announces the Full Commercial Launch of WaveForm A 3D Printed Anterior Lumbar Interbody

Retrieved on: 
月曜日, 6月 19, 2023
Surgery, Medical Devices, Hospitals, Biotechnology, Other Health, Physical Therapy, Managed Care, Health, General Health, Ketan, Waveform, Surgeon, 3D, Porosity, Degenerative disc disease, Multimedia, Research, Patient, Tissue engineering, Arbitrary waveform generator, PEEK, Environment, 3D printing, Engineered wood, Dentistry, Meridian, Electron-beam additive manufacturing

(NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the full commercial launch of the WaveForm® A interbody for Anterior Lumbar Interbody Fusion (ALIF) procedures.

Key Points: 
  • (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the full commercial launch of the WaveForm® A interbody for Anterior Lumbar Interbody Fusion (ALIF) procedures.
  • The WaveForm A interbody seamlessly integrates with the company’s Meridian ALIF system for treating patients in need of fusion due to degenerative disc disease.
  • Meridian is compatible with both the WaveForm A interbody and the company’s Reef™ A interbody featuring its proprietary NanoMetalene® surface technology and Reef Topography™.
  • With the launch of WaveForm A, the Meridian system can more completely address the approximately $200 million dollar ALIF market segment in the U.S.1
    The 3D printed WaveForm A implants feature WaveForm® technology, a repeating and continuous wave-like structure.